Diabetes Mellitus, Type 2 Clinical Trial
Official title:
Starter Kit Study in Insulin naïve Patients With Type 2 Diabetes
Verified date | February 2020 |
Source | Hvidovre University Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The concept consists of an initial period (two weeks) of intensive data capture by use of continuous glucose monitoring (CGM) during basal insulin initiation, followed by a second period (variable duration) of basal insulin titration guided by self monitored blood glucose. Data captured during the first period are used as input to an algorithm that estimates the optimal daily dose for the individual patient. The estimated optimal daily dose is used to guide the titration of the basal insulin during the second period. The goal is to safely and successfully achieve blood glucose targets. The concept is based on the use of basal insulin degludec (Tresiba, Novo Nordisk A/S).
Status | Completed |
Enrollment | 8 |
Est. completion date | January 15, 2020 |
Est. primary completion date | November 1, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: - Type 2 diabetes - Age 18-75 years - HbA1c 53-86 mmol/mol (7.0-10.0%) - BMI 20-40 kg/m2 - Insulin-naïve - Willingness to use CGM consistently during the study period and send/receive data and dose advice to/from HCP via a mobile phone - Signed informed consent prior to any study procedures Exclusion Criteria: - Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods - Active proliferative retinopathy - Mean blood glucose > 15 mmol/l the week prior to screening - Blood glucose > 20 mmol/l on the screening day - Non-fasting ketones > 0,5 mmol/l on the screening day - Use of sulfonylurea within 14 days prior to or during the study period - Change in other antidiabetic medicine than basal insulin during the study period - Use of corticosteroids within 30 days prior to or during the study period - Marked change in lifestyle within 30 days prior to or during the study period as assessed by the investigator - People with type 2 diabetes that suffer from conditions which make tight diabetes control undesirable, e.g. severe cardiovascular disease, according to the investigator - Other concomitant medical or psychological condition that according to the investigator's assessment makes the patient unsuitable for study participation - Overall treatment |
Country | Name | City | State |
---|---|---|---|
Denmark | Hvidovre University Hospital | Hvidovre |
Lead Sponsor | Collaborator |
---|---|
Signe Schmidt | Novo Nordisk A/S, Technical University of Denmark |
Denmark,
Aradóttir TB, Bengtsson H, Jensen ML, Poulsen NK, Boiroux D, Jensen LL, Schmidt S, Nørgaard K. Feasibility of a New Approach to Initiate Insulin in Type 2 Diabetes. J Diabetes Sci Technol. 2020 Jan 15:1932296819900240. doi: 10.1177/1932296819900240. [Epub — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Accuracy of estimate 1 | Accuracy of the estimated optimal daily dose (calculated by the Starter Kit algorithm based on continuous glucose monitoring (CGM) data collected during day 1-14) compared with the observed optimal daily dose in percentage deviation. In this context, optimal daily dose is the dose considered to keep fasting glucose levels below 6 mmol/L. |
through study completion, 12 weeks | |
Primary | Accuracy of estimate 2 | The number of estimated optimal daily doses by the Starter Kit Algorithm at two weeks that fall within a patient specific confidence interval. The confidence interval is determined using the Starter Kit Algorithm at the end of study, one interval for each patient. Upper boundary: the optimal daily dose estimated to bring lowest hour of CGM values within a day to 4.0 mmol/L Lower boundary: the optimal daily dose estimated to bring lowest hour of CGM values within a day to 6.0 mmol/L |
through study completion, 12 weeks | |
Secondary | Accuracy of estimate 3 | Accuracy of the estimated optimal daily dose (calculated based on self-monitored blood glucose data collected during day 1-14) compared with the observed optimal daily dose. | through study completion, 12 weeks | |
Secondary | Number of patients in glucose target | Number of participants in target at end of study | through study completion, 12 weeks | |
Secondary | Algorithm deviations | Number of titration algorithm deviations due to risk of hypoglycemia (based on evaluation of CGM data) | 12 weeks (total duration of study) | |
Secondary | Quality of treatment 1 | Qualitative assessment by the investigator of participants who do not reach the observed optimal daily dose within 12 weeks: Frequency of participants who are in need of additional basal insulin to achieve the target blood glucose. | through study completion, 12 weeks | |
Secondary | Quality of treatment 2 | Qualitative assessment by the investigator of participants who do not reach the observed optimal daily dose within 12 weeks: Frequency of participants who are in need of additional drugs to achieve the target blood glucose. | through study completion, 12 weeks | |
Secondary | Number of self-monitored blood glucose values =3.9 mmol/L | Number of self-monitored blood glucose values =3.9 mmol/L | 12 weeks (total duration of study) | |
Secondary | Number of self-monitored blood glucose values =3.0 mmol/L | Number of self-monitored blood glucose values =3.0 mmol/L | 12 weeks (total duration of study) | |
Secondary | Severe hypoglycemia | Number of severe hypoglycemic events (defined as severe cognitive impairment requiring external assistance for recovery). | 12 weeks (total duration of study) | |
Secondary | Time spent in hypoglycemia | Time spent in hypoglycemia (<3.9 mmol/L) assessed by CGM during the first four study days (days without insulin) and the last four study days (days with optimal daily insulin dose). | 8 days (first four and last four days of study) | |
Secondary | Time spent in hyperglycemia | Time spent in hyperglycemia (>10 mmol/L) assessed by CGM during the first four study days (days without insulin) and the last four study days (days with optimal daily insulin dose). | 8 days (first four and last four days of study) | |
Secondary | Time spent in normoglycemia | Time spent in normoglycemia (3.9-10.0 mmol/L) assessed by CGM during the first four study days (days without insulin) and the last four study days (days with optimal daily insulin dose). | 8 days (first four and last four days of study) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05666479 -
CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
|
||
Completed |
NCT05647083 -
The Effect of Massage on Diabetic Parameters
|
N/A | |
Active, not recruiting |
NCT05661799 -
Persistence of Physical Activity in People With Type 2 Diabetes Over Time.
|
N/A | |
Completed |
NCT03686722 -
Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin
|
Phase 1 | |
Completed |
NCT02836704 -
Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose)
|
Phase 4 | |
Completed |
NCT01819129 -
Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes
|
Phase 3 | |
Completed |
NCT04562714 -
Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy
|
N/A | |
Completed |
NCT02009488 -
Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1 | |
Completed |
NCT05896319 -
Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2
|
N/A | |
Recruiting |
NCT05598203 -
Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes
|
N/A | |
Completed |
NCT05046873 -
A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People
|
Phase 1 | |
Completed |
NCT04030091 -
Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus
|
Phase 4 | |
Terminated |
NCT04090242 -
Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes
|
N/A | |
Completed |
NCT03604224 -
A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
|
||
Completed |
NCT03620357 -
Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D)
|
N/A | |
Completed |
NCT01696266 -
An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
|
||
Completed |
NCT03620890 -
Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy
|
Phase 4 | |
Withdrawn |
NCT05473286 -
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
|
||
Not yet recruiting |
NCT05029804 -
Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes
|
N/A | |
Completed |
NCT04531631 -
Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes
|
Phase 2 |